Primaquine radical cure of Plasmodium vivax malaria: a risk-benefit analysis

间日疟疾发病率很高，每年有1亿多临床病例，并可导致疾病复发和慢性贫血。唯一有效的根治间日疟原虫的方法是使用伯氨喹，但在一些患者中可能导致严重的溶血。我们的研究旨在利用已发表临床试验的荟萃分析数据和大型多中心试验的个体患者结果，确定给予伯氨喹治疗间日疟疾的风险和益处。

Vivax malaria causes significant morbidity with over 100 million clinical cases each year and can cause a relapsing illness and chronic anaemia. The only available radical cure of P. vivax requires administration of primaquine, which can cause severe haemolysis in some patients. Our research aims to determine the risks and benefits of giving primaquine to cure vivax malaria using data from meta-analyses of published clinical trials and individual patient results from large multicentre trials.